INVO insider filings
INVO Bioscience, Inc. — 41 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-05-22. Screen INVO transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for INVO between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — INVO Bioscience, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-05-22 | 4 | Shum Steve — Chief Executive Officer, Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | Ryan Barbara — Director | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | Messina Rebecca — Director | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | Campbell Michael Jos. — Chief Operating Officer, Director | Grant/award (A): 83,000 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | Szot Matthew K — Director | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | Goren Andrea — Chief Financial Officer | Grant/award (A): 81,000 (derivative) @ $0 | EDGAR |
| 2023-05-22 | 4 | DAVIS TRENT D — Director | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2022-06-03 | 4 | Shum Steve — Chief Executive Officer, Director | Purchase (P): 58,885 @ $0.95 | EDGAR |
| 2022-06-03 | 4 | Ryan Barbara — Director | Purchase (P): 10,526 @ $0.95 | EDGAR |
| 2022-06-03 | 4 | Segal Jeffrey — Director | Purchase (P): 9,211 @ $0.95 | EDGAR |
| 2022-06-03 | 4 | Campbell Michael Jos. — Chief Operating Officer, Director | Purchase (P): 10,526 @ $0.95 | EDGAR |
| 2022-06-03 | 4 | Messina Rebecca — Director | Purchase (P): 9,868 @ $0.95 | EDGAR |
| 2022-06-03 | 4 | Doody Kevin — Medical Director, Director | Purchase (P): 177,306 @ $0.95 | EDGAR |
| 2022-06-03 | 4 | Szot Matthew K — Director | Purchase (P): 14,474 @ $0.95 | EDGAR |
| 2022-06-03 | 4 | Goren Andrea — Chief Financial Officer | Purchase (P): 52,632 @ $0.95 | EDGAR |
| 2022-06-03 | 4 | DAVIS TRENT D — Director | Purchase (P): 11,184 @ $0.95 | EDGAR |
| 2022-01-18 | 4 | Doody Kevin — Medical Director, Director | Grant/award (A): 7,480 @ $0 · Grant/award (A): 9,088 (derivative) @ $0 | EDGAR |
| 2022-01-18 | 4 | Segal Jeffrey — Director | Grant/award (A): 8,034 @ $0 · Grant/award (A): 9,762 (derivative) @ $0 | EDGAR |
| 2022-01-18 | 4 | Campbell Michael Jos. — Chief Operating Officer, Director | Grant/award (A): 15,236 @ $0 · Grant/award (A): 18,513 (derivative) @ $0 | EDGAR |
| 2022-01-18 | 4 | Shum Steve — Chief Executive Officer, Director | Grant/award (A): 20,111 @ $0 · Grant/award (A): 57,018 (derivative) @ $0 | EDGAR |
| 2022-01-18 | 4 | Messina Rebecca — Director | Grant/award (A): 8,311 @ $0 · Grant/award (A): 10,098 (derivative) @ $0 | EDGAR |
| 2022-01-18 | 4 | Ryan Barbara — Director | Grant/award (A): 8,588 @ $0 · Grant/award (A): 10,435 (derivative) @ $0 | EDGAR |
| 2022-01-18 | 4 | Szot Matthew K — Director | Grant/award (A): 10,250 @ $0 · Grant/award (A): 12,454 (derivative) @ $0 | EDGAR |
| 2022-01-18 | 4 | Goren Andrea — Chief Financial Officer | Grant/award (A): 5,361 @ $0 · Grant/award (A): 15,197 (derivative) @ $0 | EDGAR |
| 2022-01-18 | 4 | DAVIS TRENT D — Director | Grant/award (A): 8,865 @ $0 · Grant/award (A): 10,771 (derivative) @ $0 | EDGAR |
| 2021-10-12 | 4 | AWM Investment Company, Inc. — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2021-10-07 | 4 | Shum Steve — Chief Executive Officer, Director | Purchase (P): 30,674 @ $3.26 | EDGAR |
| 2021-10-07 | 4 | Goren Andrea — Chief Financial Officer | Purchase (P): 30,674 @ $3.26 | EDGAR |
| 2021-05-13 | 4 | Messina Rebecca — Director | Grant/award (A): 4,806 @ $0 · Grant/award (A): 6,239 (derivative) @ $0 | EDGAR |
| 2021-05-12 | 4 | AWM Investment Company, Inc. — 10% owner | Purchase (P): 1,000 @ $3.76 | EDGAR |
| 2021-05-11 | 4 | AWM Investment Company, Inc. — 10% owner | Purchase (P): 15,000 @ $4.08 · Purchase (P): 27,811 @ $4.08 · Purchase (P): 13,146 @ $4.00 · Purchase (P): 5,800 @ $3.97 · Purchase (P): 17,152 @ $3.95 · Purchase (P): 322 @ $3.85 · +7 more | EDGAR |
| 2021-01-05 | 4 | Shum Steve — Chief Executive Officer, Director | Grant/award (A): 180,000 (derivative) @ $0 | EDGAR |
| 2021-01-05 | 4 | Segal Jeffrey — Director | Grant/award (A): 8,838 @ $0 · Grant/award (A): 11,823 (derivative) @ $0 | EDGAR |
| 2021-01-05 | 4 | Ryan Barbara — Director | Grant/award (A): 10,148 @ $0 · Grant/award (A): 13,574 (derivative) @ $0 | EDGAR |
| 2021-01-05 | 4 | Doody Kevin — Medical Director, Director | Grant/award (A): 8,184 @ $0 · Grant/award (A): 10,947 (derivative) @ $0 | EDGAR |
| 2021-01-05 | 4 | Campbell Michael Jos. — Chief Operating Officer, Director | Grant/award (A): 165,000 (derivative) @ $0 | EDGAR |
| 2021-01-05 | 4 | Szot Matthew K — Director | Grant/award (A): 12,112 @ $0 · Grant/award (A): 16,202 (derivative) @ $0 | EDGAR |
| 2021-01-05 | 4 | DAVIS TRENT D — Director | Grant/award (A): 10,475 @ $0 · Grant/award (A): 14,012 (derivative) @ $0 | EDGAR |
| 2020-12-01 | 4 | Segal Jeffrey — Director | Grant/award (A): 1,137 @ $0 · Grant/award (A): 1,137 (derivative) @ $0 | EDGAR |
| 2020-12-01 | 4 | Ryan Barbara — Director | Grant/award (A): 2,317 @ $0 · Grant/award (A): 2,317 (derivative) @ $0 | EDGAR |
| 2020-12-01 | 4 | Szot Matthew K — Director | Grant/award (A): 2,339 @ $0 · Grant/award (A): 2,339 (derivative) @ $0 | EDGAR |
Recent 8-K events — INVO Bioscience, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-16 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-04 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-28 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-17 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-25 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events | EDGAR |
| 2026-06-22 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-16 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-02 | 8-K | 4.02 — Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-02 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=INVO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs